EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC 4.0

Secukinumab in the Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies

Afsaneh Alavi iD, Ziad Reguiai iD, Gregor B E Jemec, Alice B Gottlieb, Magdalena B Wozniak, Lorenz Uhlmann, Heng Fan, Angela Llobet Martinez, Gerard Bruin, Nicolas Thomas, Ivette Alarcon, Bruno Bieth und 2 weitere

International Journal of Dermatology · 2026

DOI: 10.1111/ijd.70025 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von Afsaneh Alavi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hidradenitis Suppurativa. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Secukinumab, a fully human, monoclonal antibody targeting interleukin‐17A, is approved for moderate‐to‐severe HS in adults. This study evaluated pharmacokinetics (PK), high‐sensitivity C‐reactive protein (hsCRP) changes, and safety of secukinumab over 52 weeks in SUNSHINE and SUNRISE Phase 3 trials.

Methods

An exploratory analysis of pooled Phase‐3 trials evaluated serum PK and safety of secukinumab 300 mg every 2 (SECQ2W) or 4 weeks (SECQ4W). A population PK model assessed the effects of body weight, disease severity, and baseline hsCRP on secukinumab serum concentration. Exposure–response analysis assessed the relationship between predicted PK and HS clinical response [HiSCR]. No confirmatory statistical testing was performed.

Results

Mean serum trough concentration at Weeks 16, 24, and 52 was ~2‐fold higher with SECQ2W vs. SECQ4W. At Week 16, exposure overlap was high, with an estimated numerical increase in HiSCR of ~3% for SECQ2W over SECQ4W. At Week 52, HiSCR levels plateaued. At Week 16, hsCRP decreased from 18.6 ± 26.3 mg/L to 12.8 ± 18.0 mg/L (SECQ2W), 15.9 ± 27.6 mg/L to 11.5 ± 18.4 mg/L (SECQ4W), and remained unchanged with placebo (14.4 ± 22.5 mg/L to 14.7 ± 23.8 mg/L); reductions were sustained through Week 52. Higher body weight, disease severity, and baseline hsCRP were associated with lower secukinumab serum concentrations. Secukinumab immunogenicity was low (< 1%), with no new safety signals.

Conclusion

Secukinumab serum concentrations in patients with HS varied with body weight, disease severity, and baseline hsCRP. SECQ2W may benefit certain patients. Secukinumab reduced hsCRP through Week 52. The safety profile of secukinumab was consistent with other approved indications, with no apparent dose–response relationship observed. Trial Registration NCT03713619 (Novartis study code CAIN457M2301). NCT03713632 (Novartis study code CAIN457M2302)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHidradenitis SuppurativaHumansSeverity of Illness IndexMaleFemaleAdultC-Reactive ProteinMiddle AgedTreatment OutcomeClinical Trials, Phase III as TopicInterleukin-17Body Weight

Stichwörter der Autor:innen

C‐reactive proteinbiological productshidradenitis suppurativainterleukin‐17monoclonal antibodies

Substanzen

secukinumabAntibodies, Monoclonal, HumanizedC-Reactive ProteinInterleukin-17

Autor:innen und Institutionen

  • Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Dermatology Department, Polyclinique Courlancy-Bezannes, Reims, France.
  • Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
  • Department of Dermatology, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Novartis Ireland Limited, Dublin, Ireland.
  • Novartis Pharma AG, Basel, Switzerland.

ORCID-Profile: Afsaneh Alavi, Ziad Reguiai

Förderung

  • Novartis Pharma

Zitieren

APA

Alavi, A., Reguiai, Z., Jemec, G. B. E., Gottlieb, A. B., Wozniak, M. B., Uhlmann, L., Fan, H., Llobet Martinez, A., Bruin, G., Thomas, N., Alarcon, I., Bieth, B., Ravichandran, S., & Kimball, A. B. (2026). Secukinumab in the Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies. International Journal of Dermatology. https://doi.org/10.1111/ijd.70025

Vancouver

Alavi A, Reguiai Z, Jemec GBE, Gottlieb AB, Wozniak MB, Uhlmann L, et al. Secukinumab in the Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies. International Journal of Dermatology. 2026. doi:10.1111/ijd.70025

BibTeX
@article{Alavi2026,
  author = {Alavi, Afsaneh and Reguiai, Ziad and Jemec, Gregor B E and Gottlieb, Alice B and Wozniak, Magdalena B and Uhlmann, Lorenz and Fan, Heng and Llobet Martinez, Angela and Bruin, Gerard and Thomas, Nicolas and Alarcon, Ivette and Bieth, Bruno and Ravichandran, Shoba and Kimball, Alexa B},
  title = {Secukinumab in the Treatment of Moderate‐to‐Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies},
  journal = {International Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ijd.70025}
}
Kostenlos starten →